459 related articles for article (PubMed ID: 25711332)
1. Prevalence of and risk factors for low bone mineral density in untreated HIV infection: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.
Carr A; Grund B; Neuhaus J; Schwartz A; Bernardino JI; White D; Badel-Faesen S; Avihingsanon A; Ensrud K; Hoy J;
HIV Med; 2015 Apr; 16 Suppl 1(0 1):137-46. PubMed ID: 25711332
[TBL] [Abstract][Full Text] [Related]
2. The rate of bone loss slows after 1-2 years of initial antiretroviral therapy: final results of the Strategic Timing of Antiretroviral Therapy (START) bone mineral density substudy.
Carr A; Grund B; Schwartz AV; Avihingsanon A; Badal-Faesen S; Bernadino JI; Estrada V; La Rosa A; Mallon P; Pujari S; White D; Wyman Engen N; Ensrud K; Hoy JF;
HIV Med; 2020 Jan; 21(1):64-70. PubMed ID: 31642586
[TBL] [Abstract][Full Text] [Related]
3. Immediate Initiation of Antiretroviral Therapy for HIV Infection Accelerates Bone Loss Relative to Deferring Therapy: Findings from the START Bone Mineral Density Substudy, a Randomized Trial.
Hoy JF; Grund B; Roediger M; Schwartz AV; Shepherd J; Avihingsanon A; Badal-Faesen S; de Wit S; Jacoby S; La Rosa A; Pujari S; Schechter M; White D; Engen NW; Ensrud K; Aagaard PD; Carr A;
J Bone Miner Res; 2017 Sep; 32(9):1945-1955. PubMed ID: 28650589
[TBL] [Abstract][Full Text] [Related]
4. CD4 T cell count is inversely associated with lumbar spine bone mass in HIV-infected men under the age of 50 years.
Kwak MK; Lee EJ; Park JW; Park SY; Kim B-; Kim TH; Suh K; Koh J-; Lee SH; Byun D-
Osteoporos Int; 2019 Jul; 30(7):1501-1510. PubMed ID: 30915506
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and risk factors for low bone mineral density in antiretroviral therapy-naive HIV-infected young men.
Paccou J; Viget N; Drumez E; Cortet B; Robineau O
Med Mal Infect; 2018 Oct; 48(7):442-448. PubMed ID: 29699830
[TBL] [Abstract][Full Text] [Related]
6. Relative contribution of HIV infection, demographics and body mass index to bone mineral density.
Cotter AG; Sabin CA; Simelane S; Macken A; Kavanagh E; Brady JJ; McCarthy G; Compston J; Mallon PW;
AIDS; 2014 Sep; 28(14):2051-60. PubMed ID: 25265073
[TBL] [Abstract][Full Text] [Related]
7. Continuous antiretroviral therapy decreases bone mineral density.
Grund B; Peng G; Gibert CL; Hoy JF; Isaksson RL; Shlay JC; Martinez E; Reiss P; Visnegarwala F; Carr AD;
AIDS; 2009 Jul; 23(12):1519-29. PubMed ID: 19531929
[TBL] [Abstract][Full Text] [Related]
8. Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation.
Grant PM; Kitch D; McComsey GA; Dube MP; Haubrich R; Huang J; Riddler S; Tebas P; Zolopa AR; Collier AC; Brown TT
Clin Infect Dis; 2013 Nov; 57(10):1483-8. PubMed ID: 23943825
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and risk factors for bone mineral density changes in antiretroviral therapy-naive human immunodeficiency virus-infected adults: a Chinese cohort study.
Zeng YQ; Xiao J; Li CL; Wang Y; Zhang L; Pang XL; Wang D; Du J; Zhao HX
Chin Med J (Engl); 2020 Dec; 133(24):2940-2946. PubMed ID: 33278100
[TBL] [Abstract][Full Text] [Related]
10. Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors.
Goh SSL; Lai PSM; Tan ATB; Ponnampalavanar S
Osteoporos Int; 2018 Mar; 29(3):595-613. PubMed ID: 29159533
[TBL] [Abstract][Full Text] [Related]
11. Dairy calcium intake and lifestyle risk factors for bone loss in hiv-infected and uninfected Mediterranean subjects.
Li Vecchi V; Soresi M; Giannitrapani L; Mazzola G; La Sala S; Tramuto F; Caruso G; Colomba C; Mansueto P; Madonia S; Montalto G; Di Carlo P
BMC Infect Dis; 2012 Aug; 12():192. PubMed ID: 22894751
[TBL] [Abstract][Full Text] [Related]
12. High prevalence of reduced bone mineral density in primary HIV-1-infected men.
Grijsen ML; Vrouenraets SM; Steingrover R; Lips P; Reiss P; Wit FW; Prins JM
AIDS; 2010 Sep; 24(14):2233-8. PubMed ID: 20616695
[TBL] [Abstract][Full Text] [Related]
13. Early changes in bone turnover and inflammatory biomarkers and clinically significant bone mineral density loss over 48 weeks among HIV-infected patients with virological failure of a standard first-line antiretroviral therapy regimen in the SECOND-LINE study.
Mwasakifwa GE; Amin J; White CP; Center JR; Kelleher A; Boyd MA
HIV Med; 2020 Sep; 21(8):492-504. PubMed ID: 32573910
[TBL] [Abstract][Full Text] [Related]
14. Unravelling hip-spine bone mineral density discordance in people living with HIV.
Vizcarra P; Rosillo M; Del Rey JM; Moreno A; Vivancos MJ; Casado JL
J Bone Miner Metab; 2022 Nov; 40(6):990-997. PubMed ID: 36038672
[TBL] [Abstract][Full Text] [Related]
15. Reduced bone mineral density among HIV-infected patients in Taiwan: prevalence and associated factors.
Tsai MS; Hung CC; Liu WC; Chen KL; Chen MY; Hsieh SM; Sheng WH; Sun HY; Shih TT
J Microbiol Immunol Infect; 2014 Apr; 47(2):109-15. PubMed ID: 23073318
[TBL] [Abstract][Full Text] [Related]
16. Is bone loss linked to chronic inflammation in antiretroviral-naive HIV-infected adults? A 48-week matched cohort study.
Hileman CO; Labbato DE; Storer NJ; Tangpricha V; McComsey GA
AIDS; 2014 Jul; 28(12):1759-67. PubMed ID: 24871454
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and predictors of low bone mineral density and fragility fractures among HIV-infected patients at one Italian center after universal DXA screening: sensitivity and specificity of current guidelines on bone mineral density management.
Mazzotta E; Ursini T; Agostinone A; Di Nicola AD; Polilli E; Sozio F; Vadini F; Pieri A; Trave F; De Francesco V; Capasso L; Borderi M; Manzoli L; Viale P; Parruti G
AIDS Patient Care STDS; 2015 Apr; 29(4):169-80. PubMed ID: 25692868
[TBL] [Abstract][Full Text] [Related]
18. Role of bone mineral density in predicting morphometric vertebral fractures in patients with HIV infection.
Porcelli T; Gotti D; Cristiano A; Maffezzoni F; Mazziotti G; Focà E; Castelli F; Giustina A; Quiros-Roldan E
Osteoporos Int; 2014 Sep; 25(9):2263-9. PubMed ID: 25056799
[TBL] [Abstract][Full Text] [Related]
19. Bone mass and mineral metabolism in HIV+ postmenopausal women.
Yin M; Dobkin J; Brudney K; Becker C; Zadel JL; Manandhar M; Addesso V; Shane E
Osteoporos Int; 2005 Nov; 16(11):1345-52. PubMed ID: 15754081
[TBL] [Abstract][Full Text] [Related]
20. Low bone mass prevalence, therapy type, and clinical risk factors in an HIV-infected Brazilian population.
Pinto Neto LF; Ragi-Eis S; Vieira NF; Soprani M; Neves MB; Ribeiro-Rodrigues R; Miranda AE
J Clin Densitom; 2011; 14(4):434-9. PubMed ID: 22051092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
